TransCode Therapeutics, Inc. fell 10.8% on Friday, November 20, 2026, on 60,671 shares. No headline about RNAZ came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
TransCode Therapeutics, Inc. (RNAZ:NASDAQ) closed at $1.16 on November 20, 2026, down 10.77% on the day. The stock trades 90.8% below its 52-week high of $12.60 and 14.9% above its 52-week low of $1.01. Over the past year, it lost 87.2%. TransCode Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 20, 2025, RNAZ closed higher on 103 days (41%). Its best day was January 26, 2026 (+25.03%) and its worst was July 24, 2026 (-18.21%). The stock moved 10% or more in a single session 22 times. It opened at least 5% above the previous day's high 5 times.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
Find more stocks like RNAZ with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.